Unraveling the mechanism of JPI-547 in human pancreatic cancer cells through transcriptome analysis.
This study aimed to elucidate the mechanism underlying the action of the dual PARP/Tankyrase inhibitor JPI-547 through RNA sequencing. Focusing on human pancreatic cancer cell lines with either homologous recombination repair deficiency or Wnt-addiction, the investigation sought to uncover critical insights into the compound's mode of action.